Abbott Laboratories (ABT)
| Previous Close | 110.27 |
| Open | 110.84 |
| Bid | 111.72 x 800 |
| Ask | 111.75 x 900 |
| Day's Range | 110.71 - 112.13 |
| 52 Week Range | 101.24 - 142.60 |
| Volume | |
| Avg. Volume | 5,054,212 |
| Market Cap | 194.946B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | 23.24 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.88 (1.74%) |
| Ex-Dividend Date | Jul 14, 2022 |
| 1y Target Est | N/A |
- News Direct
HBCUS, Industry Partners Launch Initiative To Diversify and Strengthen Cybersecurity Workforce
BALTIMORE, August 1, 2022 /3BL Media/ - To address the urgent cybersecurity talent needs in the U.S., Advancing Minorities' Interest in Engineering (AMIE) announced a new collaboration to support c...
- News Direct
Survey: Telehealth Improves Access to Parkinson's Care
Parkinson's Foundation survey says vast majority find greater access to remote care via NeuroSphere Virtual Clinic.
- CNW Group
Abbott Introduces Canada's First Remote Neuromodulation Patient-Care Technology, NeuroSphere™ Virtual Clinic, to Treat People with Chronic Pain and Movement Disorders*
Abbott (NYSE: ABT) announces the Health Canada licencing†of NeuroSphere™ Virtual Clinic, a remote programming technology that is the first of its kind in Canada and is compatible with Abbott's suite of neuromodulation technologies. NeuroSphere Virtual Clinic has the potential to increase access to optimal treatment for patients living with chronic pain, Parkinson's disease, or essential tremors who might otherwise have difficulty receiving care from their healthcare provider due to location or
